Opioid Signalling

Castagnoli, L., Jassal, B., Le Novere, N., Schmidt, EE.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of Creative Commons Attribution 4.0 International (CC BY 4.0) License. For more information see our license.

22/08/2019
Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references


Reactome database release: 69

This document contains 4 pathways and 2 reactions (see Table of Contents)
Opioid Signalling

Stable identifier: R-HSA-111885

Opioids are chemical substances similar to opiates, the active substances found in opium (morphine, codeine etc.). Opioid action is mediated by the receptors for endogenous opioids; peptides such as the enkephalins, the endorphins or the dynorphins. Opioids possess powerful analgesic and sedative effects, and are widely used as pain-killers. Their main side-effect is the rapid establishment of a strong addiction. Opioids receptors are G-protein coupled receptors (GPCR). There are four classes of receptors: mu (MOR), kappa (KOR) and delta (DOR), and the nociceptin receptor (NOP).

Literature references


Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Author/Reviewer</th>
<th>Edited By</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004-03-31</td>
<td>Authored</td>
<td>Jassal, B., Le Novere, N.</td>
</tr>
<tr>
<td>2008-11-06</td>
<td>Reviewed</td>
<td>Castagnoli, L.</td>
</tr>
<tr>
<td>2019-05-10</td>
<td>Edited</td>
<td>Schmidt, EE.</td>
</tr>
</tbody>
</table>
The binding of an opiate peptide to the mu opiate receptor stabilises the receptor conformation in a state of high affinity, both for the ligand itself, and for the G-protein.

**Preceded by:** Opioid dissociates from MOR

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004-03-31</td>
<td>Authored</td>
<td>Jassal, B., Le Novere, N.</td>
</tr>
<tr>
<td>2008-11-06</td>
<td>Reviewed</td>
<td>Castagnoli, L.</td>
</tr>
<tr>
<td>2008-11-06</td>
<td>Edited</td>
<td>Jassal, B.</td>
</tr>
</tbody>
</table>
G-protein activation

Location: Opioid Signalling

Stable identifier: R-HSA-202040

Receptor activated heterotrimeric G proteins consist of the Galphα and the tightly associated Gbeta-gamma subunits. When a ligand binds to a G protein-coupled receptor, it stabilises a conformation with an high affinity for the G-protein bound to GDP. GDP is then exchanged for GTP on the Galphα subunit. This exchange triggers the dissociation of the Galphα subunit from the Gbeta-gamma dimer and the receptor. Galphα-GTP and Gbeta-gamma, can then modulate different signalling cascades and effector proteins, while the receptor is able to activate another G protein, resulting in an amplification cascade. The Galphα subunit will eventually hydrolyze the attached GTP to GDP by its inherent enzymatic activity, allowing it to reassociate with Gbeta-gamma and start a new cycle.

Literature references


Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author/Reviewer</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004-03-31</td>
<td>Authored</td>
<td>Jassal, B., Le Novere, N.</td>
</tr>
<tr>
<td>2008-11-06</td>
<td>Reviewed</td>
<td>Castagnoli, L.</td>
</tr>
<tr>
<td>2008-11-06</td>
<td>Edited</td>
<td>Jassal, B.</td>
</tr>
</tbody>
</table>
Opioid dissociates from MOR

**Location:** Opioid Signalling

**Stable identifier:** R-HSA-167427

**Type:** dissociation

**Compartments:** extracellular region, plasma membrane

Different ligands of the MOR receptor can promote MOR phosphorylation, uncoupling, endocytosis or inactivation. For example, the endogenous peptide ligands at the MOR induce rapid desensitization, endocytosis and rapid receptor recycling. By contrast, morphine induces little to no endocytosis, tolerance and dependence. The agonist-dependent phosphorylation of opioid receptors changes the receptor conformation and increases the affinity of the receptors for cytosolic beta-arrestin proteins. This results in an uncoupling of G protein signalling and recruitment of the endocytotic machinery leading to receptor internalization and rapid resensitization. By contrast, PKC phosphorylation by non internalizing opioid ligands (e.g., morphine) cause receptors to remain inactivated in the plasma membrane, leading to signaling desensitization and opioid tolerance. In this case receptors appear to require activity of a phosphatase to be resensitized.

**Followed by:** Opioid binds MOR

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Editions</th>
<th>Authors</th>
<th>Editions</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004-03-31</td>
<td>Authored</td>
<td>Jassal, B., Le Novere, N.</td>
</tr>
<tr>
<td>2008-11-06</td>
<td>Reviewed</td>
<td>Castagnoli, L.</td>
</tr>
<tr>
<td>2008-11-06</td>
<td>Edited</td>
<td>Jassal, B.</td>
</tr>
</tbody>
</table>
**G-protein mediated events**

**Location:** Opioid Signalling

**Stable identifier:** R-HSA-112040

**Compartments:** plasma membrane, endoplasmic reticulum membrane, endoplasmic reticulum lumen, nucleoplasm, cytosol

When dissociated Galpha-GTP and Gbeta-gamma can activate or inhibit different signalling cascades and effector proteins. The precise pathways depends on the identity of the alpha and beta/gamma subtypes.

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004-03-31</td>
<td>Authored</td>
<td>Jassal, B., Le Novere, N.</td>
</tr>
<tr>
<td>2008-11-06</td>
<td>Reviewed</td>
<td>Castagnoli, L.</td>
</tr>
<tr>
<td>2008-11-06</td>
<td>Edited</td>
<td>Jassal, B.</td>
</tr>
</tbody>
</table>
Dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP-32), was identified as a major target for dopamine and protein kinase A (PKA) in striatum. Recent advances now indicate that regulation DARPP-32 phosphorylation provides a mechanism for integrating information arriving at dopaminceptive neurons, in multiple brain regions, via a variety of neurotransmitters, neuromodulators, neuropeptides, and steroid hormones. Activation of PKA or PKG stimulates DARPP-32 phosphorylation at Thr34, converting DARPP-32 into a potent inhibitor of protein phosphatase-1 (PP-1). DARPP-32 is also phosphorylated at Thr75 by Cdk5, converting DARPP-32 into an inhibitor of PKA. Thus, DARPP-32 has the unique property of being a dual-function protein, acting either as an inhibitor of PP-1 or of PKA.

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004-03-31</td>
<td>Authored</td>
<td>Jassal, B., Le Novere, N.</td>
</tr>
<tr>
<td>2008-11-06</td>
<td>Reviewed</td>
<td>Castagnoli, L.</td>
</tr>
<tr>
<td>2008-11-06</td>
<td>Edited</td>
<td>Jassal, B.</td>
</tr>
</tbody>
</table>
Table of Contents

Introduction

Opioid Signalling

Opioid binds MOR

G-protein activation

Opioid dissociates from MOR

G-protein mediated events

DARPP-32 events

Table of Contents